{
  "id": 9074327,
  "title": "Bolt Biotherapeutics CEO Quinn sells $58,402 in stock",
  "url": "https://urgent.news/2026/09/22/bolt-biotherapeutics-ceo-quinn-sells-58-402-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-22T03:31:09.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/bolt-biotherapeutics-ceo-quinn-sells-58402-in-stock-93CH-4909845"
  },
  "original_language": "en",
  "account": "William P. Quinn, the President, CEO, and CFO of Bolt Biotherapeutics, Inc., divested a total of $58,402 worth of common stock over three days in September 2026. The stock prices during this period ranged from $3.15 to $4.14. These transactions were made to cover tax withholding obligations related to the vesting of restricted stock units granted on October 22, 2025. Quinn's stock sales came at a time when the stock experienced a decline of 11% over the previous week and a 34% decrease year-to-date. Despite this recent slump, InvestingPro analysis suggests the stock is currently undervalued, trading near its 52-week low of $3.10. It is noteworthy that Quinn had previously acquired shares of Bolt Biotherapeutics in June 2026, purchasing 637 shares at a price of $3.876 per share, totaling $2,469, through the company's Employee Stock Purchase Plan.",
  "summary": null,
  "key_points": [
    "CEO William P. Quinn sold $58,402 worth of Bolt Biotherapeutics stock in September 2026.",
    "Stock prices fluctuated between $3.15 and $4.14 during the sales period.",
    "Quinn acquired 637 shares in June 2026 through the Employee Stock Purchase Plan."
  ],
  "editors_take": "The CEO's stock sale to cover tax obligations suggests a routine transaction rather than a change in confidence in the company's prospects, especially given his recent share purchase.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}